New Test for Tumor-Antigen 4 in Cancer Diagnosis
Author Information
Author(s): N. Mino-Miyagawa, Y. Kimura, K. Hamamoto
Primary Institution: Department of Radiology, School of Medicine, Ehime University
Hypothesis
The new immunoradiometric assay (IRMA) method will provide more accurate detection of tumor-antigen 4 (TA-4) levels in patients with squamous cell carcinoma (SCC) compared to the conventional radioimmunoassay (RIA) method.
Conclusion
The new IRMA method significantly enhances the diagnostic detectability of serum TA-4 in patients with squamous cell carcinoma.
Supporting Evidence
- The IRMA method showed higher positive ratios for TA-4 levels in SCC compared to the RIA method.
- Serum TA-4 levels were significantly higher in patients with SCC than in healthy controls.
- The IRMA method improved sensitivity and accuracy in detecting TA-4 levels.
- Positive ratios for TA-4 were 2-3 times higher in SCC of the larynx, tongue, and pharynx using the IRMA method.
Takeaway
Doctors found a new way to test for a cancer marker that helps identify certain types of cancer better than the old method.
Methodology
The study measured serum TA-4 levels using both the new IRMA method and the conventional RIA method in patients with various types of cancer and healthy controls.
Limitations
The diagnostic usefulness of TA-4 was limited in early stages of SCC and in certain organs.
Participant Demographics
181 patients with squamous cell carcinoma, 34 patients with other types of lung cancer, 35 patients with benign diseases, and 59 healthy volunteers.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website